AGEN logo

AGEN Agenus Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$7.32
+0.32 (+4.57%)

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also a…

Market Cap: $304.82Mwww.agenusbio.com

Price (90d)

$6.96
$2.88$4.69$6.49$8.30
Apr 30Aug 7

Signal Score (90d)

80
80
Aug 7Aug 7

Quote

Day Range
$6.88 – $7.46
52-Week Range
$2.71 – $8.85
Volume
$1.24M
Market Cap
$304.82M
50-Day Avg
$4.85
200-Day Avg
$3.94
Prev Close
$7.00
Open
$6.88

Valuation & Ratios

P/E Ratio
-923.53
EPS
$0.00
P/B Ratio
-0.34
P/S Ratio
0.82
Debt/Equity
-1.24
Current Ratio
0.41
Dividend Yield
+0.0%
Gross Margin
+29.6%

Returns & Efficiency

Return on Equity
-0.0%
Return on Assets
+0.1%
FCF Yield
-170.2%
EV/EBITDA
6.84

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$114.20M$115.0K$-0.00
2024$103.46M$-227.21M$-10.59
2023$156.31M$-245.76M$-13.75
2022$98.02M$-220.07M$-15.64
2021$295.67M$-23.93M$-2.11

Social Signal Score

30
5d
30d
30
1 mentions
+39.2%
60d
30
1 mentions
+133.6%
90d
30
1 mentions
+94.4%
news: 1

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $0.02 per share

3of 7 quarters beat consensus

Typical surprise -26.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.01 vs $0.04miss
  • Mon, May 11$1.02 vs $2.10miss
  • Mon, Mar 16$0.56 vs $-1.27beat
  • Mon, Nov 10$1.94 vs $2.63miss
  • Mon, Aug 11$-1.00 vs $-0.78miss
  • Mon, May 12$-1.03 vs $-1.61beat

Estimates and results for AGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

Project earnings forward and see what return today's price implies.

EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.

EPS in 5 years
$0.01
Implied price
$0.10
Return from $7.32
-57.4% a year

To earn 15.0% a year on these assumptions you'd need to buy at $0.05 -99.3% below today's price.

How sensitive is that answer?

Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.

growth \ P/E1215182124
-2.0%-64.4%-62.8%-61.4%-60.2%-59.1%
3.0%-62.6%-60.9%-59.4%-58.1%-57.0%
8.0%-60.7%-59.0%-57.4%-56.1%-54.9%
13.0%-58.9%-57.1%-55.5%-54.1%-52.8%
18.0%-57.1%-55.2%-53.5%-52.0%-50.7%

This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.

Mentions (1)

  • Newszacks.com·7d ago·Negative

    Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.

    View source ↗